Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

05 Days

115 Speakers

Conference Schedule

Thursday
October

03

07:30

Registrations

08:00 | 📍CMR Theatre

Opening Ceremeony

Angela Caro, ISoP President, Colombia

.

Omar Aimer Co-Chair

Omar Aimer, LOC Chair, Canada

Omar Aimer Co-Chair

Maribel Salas, SC Chair, USA

08:30 |📍CMR Theatre

P1: Current Status of Pharmacovigilance in the Digital Era Around the World

Omar Aimer Co-Chair

Omar Aimer, NASoP President, Canada

Panel
Omar Aimer Co-Chair

Pamela Aung-Thin, Health Canada

Omar Aimer Co-Chair

Shanthi Pal, WHO, Switzerland

Narayan Nair, US FDA, USA

Omar Aimer Co-Chair

Hisham S. AL Jadhey, SFDA, KSA

Thomas Stammschulte, SwissMedic

Alison Cave, MHRA, United Kingdom

Luis Pinheiro, EMA, Netherlands

10:00

Coffee Break

10:30 |📍CMR Theatre

S1: Artificial Intelligence in Pharmacovigilance from the Industry Perspective.

Omar Aimer Co-Chair

Felix Arellano, Roche, Spain

Omar Aimer Co-Chair

Patrick Caubel, Pfizer, USA

Applicability of Large Language Models (LLM)
to case weighting and taxonomic data extraction in Pharmacovigilance

Omar Aimer Co-Chair

Veronique Kugener, Takeda, USA

Algorithms for causality assessments and predictive signal detection, pro and cons

Omar Aimer Co-Chair

Mariette Boerstoel, BMS, USA

Gen AI in PV: Hallucination or Reality?

Parallel

10:30 |📍CMR Cartier

S2: PV of innovative oncology-targeted therapies and immunotherapy.

Omar Aimer Co-Chair

Yvonne Nanciu, Bayer, Germany

Christine Dabrowski, GSK, USA

Immunotherapy and how It has changed the PV landscape

Omar Aimer Co-Chair

Michael von Forstner, Mesama, Switzerland

Signal Detection and Management for innovative therapies – utilizing RWD and AI

Mircea Ciuca, CSL Behring, Switzerland

An overview of the high unmet need in immunotherapy and beyond from the women´s health perspective

Oral presentations

Safety profile of Immune Checkpoint Inhibitors: an Updated Analysis of the Italian Spontaneous Reporting System Databas. Paola Maria Cutroneo

Literature analysis on immune checkpoint inhibitors-related hemophagocytic lymphohistiocytosis. Shenao Jing 

Parallel

10:30 |📍CMR International

S3: Digital transformation of pharmacovigilance in pregnancy.

Omar Aimer Co-Chair

Ushma Mehta, Cape Town University, South Africa

Ushma Mehta, Cape Town University, South Africa

Innovations in Pregnancy PV

Miriam C. J. M. Sturkenboom, University Medical Center Utrecht, Netherlands

Towards sustainable global collaboration on medicines safety in pregnancy and lactation? Lessons learned from ConcePTION and CONSIGN.

Omar Aimer Co-Chair

Anick Berard, Université de Montréal, Canada

The Canadian Mother-Child Initiative on Drug Safety in Pregnancy (CAMCCO).

Agnes Kant, Lareb, Netherlands

Lareb Pregnancy Drug Register

Oral presentation

Assessing the Involvement of Pregnant Women in Reporting Adverse Events Following Vaccination in Uganda. Victoria Prudence Nambasa

12:00

Lunch

13:30 |📍CMR Theatre

S4: RWE to identify, assess or monitor safety signals in digital era.

Omar Aimer Co-Chair

Gianluca Trifiro, Verona University, Italy

Darmendra Ramcharran, GSK, UK

Can AI improve RWEgeneration for safety signal management?

Omar Aimer Co-Chair

Stefania Spila Alegian/Marco Massari, Italy

Large scale distributed database networks for postmarketing surveillance of drugs and vaccines: the Italian experience

Omar Aimer Co-Chair

Luis Pinheiro, EMA, Netherlands

How RWE can support informed regulatory decision making? The European Medicine Agency -promoted Darwin- EU project

Omar Aimer Co-Chair

Niklas Noren, UMC, Sweden

Recommendations for the use of RWE to inform decision-making throughout pharmacovigilance signal management

Parallel

13:30 |📍CMR Cartier

S5: Safety Challenges of New-Generation Therapeutic.

Jeremy Jokinen, BMS, USA

Dr. Dirk Mentzer, MD, Paul-Ehrlich-Institut Germany

Challenges and specific aspect of pharmacovigilance of biomedicines and genetherapy

Kaori Nomura Ph.D, MPH, Teikyo Heisei University, Japan

How Japan’s approach promotes evaluation and vigilance on cell and gene therapy products

James Wabby, Abbvie, USA

Safety Challenges of Combination Advanced Therapeutics

Parallel

13:30 |📍CMR International

S6: Review of policy/ legislation/ regulation that can influence ecopharmacovigilance.

Joseph Mitchell, UMC, Sweden

Dr. Ratinder Jhaj, AIIMS Bhopal, India

Ecopharmacovigilance: Introduction and overview

Joseph Mitchell, UMC, Sweden

A Description of Environment-Related Reporting for Medicines in VigiBase

Soko Setoguchi, Rugters , USA

Interplay Between Medication Use and Climate Change: How Use of Medications Impact Health Outcomes and Planetary Health in Era of Climate Change

Oral Presentation

Targeted detection of pharmaceutical residues in fish and macroinvertebrates around the wastewater treatment at Yaounde University Teaching Hospital , Cameroon, Tchadji Mayoudom Vanessa Edwige

15:00

Coffee Break

15:30 |📍CMR Theatre

S7: Collaborative Initiatives for Safer Medications: Unifying Global Pharmacovigilance in the joint mission to prevent errors

Omar Aimer Co-Chair

Alem Zekarias, UMC, Sweden

Global patterns and trends in medication error reporting: a descriptive analysis of VigiBase

Brian Edwards & Angela Caro, ISoP

ISOP’s contributions to tackling medication errors

Rita Jew, ISMP, USA

Impact of label design on medication errors

Comfort Ogar, ISoP Africa Chapter

Medication error experiences, reflections from the African region

Carolyn Hoffman, ISMP Canada

The Essential Voice of Patients and Families in Advancing Medication Safety

Parallel

15:30 |📍CMR Cartier

S8: Unleashing the potential of digitalization in empowering patient engagement.

Omar Aimer Co-Chair

Mayada Alkhakany, Boehringer Ingelheim, UAE

Patient engagement SIG: The impact of e-pharmacovigilance on amplifying patient voices

Eva Villalba, Quebec Cancer Coalition, Canada

Patient confidentiality and consent in times of digitalization.

Alison Cave, Healthcare products Regulatory Agency UK

How digital tools can empower patients and create value for all

Oral Presentations

Standardized Approach Using Focus Groups to Obtain Healthcare Professionals feedback on Design and Content of Additional Risk Minimization Measures. Fadi Alanazi

Consumer versus Healthcare Worker Spontaneous Reporting of Adverse Events Following Immunization in sub-Saharan Africa: Insights from Uganda’s National Pharmacovigilance Database. Ronald Kiguba

Parallel

15:30 |📍CMR International 1

S9: Digital tools in Pharmacovigilance and how they can be improved.

Mark Perrott, Axian, UK

Introduction to the factors driving the adoption of digital approaches in risk management

Jean-Christophe Delumeau, Institute of Pharmacovigilance, Canada

How ISoP is responding to digital risk management opportunities

Liza Rodriguez, BMS, USA

Digital Innovation Effectiveness in Risk Management: Leveraging Technology to Mitigate and Manage Risks

Robert Massouh, GSK, UK

Challenges and Opportunities in measuring the effectiveness of Risk Minimisation Measures

Priya Bahri, EMA, Netherlands

Digital support to risk minimisation – a perspective from pharmacovigilance in a changing world

Oral Presentation

A Decision-Support Platform Powered by AI and Humans-in-the-Loop Boosts Efficiency and Assures Quality in FDA’s Pharmacovigilance. Taxiarchis Botsis

Parallel

French Session

15:30 |📍CMR International 2

S10: L’évaluation clinique des signaux en pharmacovigilance (The clinical evaluation of signals in pharmacovigilance)

Ghita Benabdallah, Centre National de Pharmacovigilance, Morocco

Dr. Houda Sefiani, Anti-poison and Pharmacovigilance Centre, Morocco

La qualité de la notification pour l’analyse en pharmacovigilance

Dr. Marie-Blanche Valnet Rabier, CHU de Besançon and French Network of Regional Centers of Pharmacovigilance , France

Évaluation du signal “Troubles de l’audition associé au vaccin ARN messager”

Dr. Edinam Amavi, WHO, Africa

Processus d’élaboration des consensus des définitions des EIPV graves et des diagnostics différentiels

Oral Presentations

Processus d’élaboration des consensus des définitions des EIPV graves et des diagnostics différentiels. Clément Cholle

Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database. François Montastruc

17:00

End of day

 

17:30  Student Meet & Greet

 

Friday
October

04

08:30 |📍CMR Theatre

P2: Preparedness for the next disaster

Omar Aimer Co-Chair

Rebecca Chandler, CEPI, Sweden

Robert T Chen, Brighton Collaboration, Canada

Tools and guidance to support robust and efficient generation of evidence of safety

Omar Aimer Co-Chair

Bruce Carleton, University of British Columbia, Canada

Genomics of vaccine safety

Danielle Craig, CEPI

Regulatory preparedness in support of generation for robust evidence with the use of vaccines in public health responses.

Alexander Precioso, CEPI

Building pharmacovigilance capacity in vaccine manufacturing partners in the Global South

10:00

Coffee Break

10:30 |📍CMR Theatre

S11: Opioids

Rania Mouchantaf

Rania Mouchantaf, Health Canada

Introduction

Bic Nguyen, US FDA, USA

US Perspective

Mohammed Adinoyi Usma, Danfodiyo University, Nigeria

African Perspective

Eilaine Morrato, DrPH MPH CPH - Loyola University, USA

Panel

Luis Pinheiro, EMA, Netherlands

Panel

Parallel

10:30 |📍CMR Cartier

S12: PV Training Needs and PV Professional Certification.

Jan Petracek, iVigee, Czech Republic

ISoP Global Pharmacovigilance Professional Certification – lessons learned

Nadja Jastrebova, UMC, Sweden

Current pharmacovigilance training needs among WHO PIDM members

Rachida Soulaymani/Ghita, Centre National de Pharmacovigilance, Morocco

Involvement in Developing PV in LMIC through capacity building

Omar Aimer, NASoP President, Canada

Pharmacovigilance and Drug Safety training in Canada

Oral Presentation

Strengthening Signal Detection and Causality Assessment Capacity Among National Pharmacovigilance Centre Staff: A Stepwise Pedagogical Approach for UMC’s Hybrid Course. Elki Sollenbring

Parallel

10:30 |📍CMR International

S13: CIOMS Guidelines on Benefit-Risk, RWE, and Artificial Intelligence.

Niklas Norén

Niklas Noren, UMC, Sweden

Ana Claudia Ianos, Pfizer, USA

Real-World Data and Real-World Evidence in Regulatory Decision Making

Taxiarchis Botsis, Johns Hopkins University USA

Artificial Intelligence in Pharmacovigilance

12:00

Lunch

13:30 |📍CMR Theatre

General Assembly

Angela Caro, ISoP President, Colombia

Executive Committee Presentation
SIGs Update
Chapters Update

Brian Edwards, ISoP Vice-President, UK

Executive Committee Presentation

Monica Tarapués, ISoP General Secretary, Ecuador

Executive Committee Presentation

Omar Aimer, ISoP Treasurer, Canada

Executive Committee Presentation

15:00

Coffee Break

15:30 |📍CMR Theatre

S14: Registries and other cohorts utilising artificial intelligence in PV: Principles and examples.

Omar Aimer Co-Chair

Ushma Mehta, Cape Town University, South Africa

Western Cape Provincial Health Data Centre (PHDC) a pharmacovigilance resource in South Africa

Katarina Ilic. ISoP Scientific Board, USA

Basic overview of registries

Leyla Sahin, US FDA, USA

FDA perspectives on registries for PV including AI

Kristian Thorlund, AI, Canada

Artificial intelligence (AI) for augmenting post-market surveillance of serious drug-induced adverse events.

Oral Presentation

 Multiple gestation births and perinatal outcomes in pregnancies secondary to clomiphene citrate treatment: a nationwide cohort study. Mathilde Bourdon

Parallel

15:30 |📍CMR Cartier

S15: Pharmacogenomics in PV.

Bruce Carleton

Bruce Carleton, University of British Columbia, Canada

Pharmacogenomic research using pharmacovigilance data: finding solutions to drug safety problems

Qun-Ying Yue, UMC, Sweden

Pharmacogenomics in Pharmacovigilance: methodology from signal detection to medicinal products labeling

Jacques Turgeon, GalenusRx, USA

Pre-emptive pharmacovigilance in the context of pharmacogenetics using biosimulations and real-world polypharmacy drug claims data from large populations

Parallel

15:30 |📍CMR International 1

S15: Automation in PV.

Francesco Salvo, Université de Bordeaux, France

Intelligent automation and artificial Intelligence in PV: strengths and limits

Mehdi Benkebil, ANSM, France

Use Cases of Artificial Intelligence in the French Pharmacosurveillance System

Ryan Walker, Oxford University, UK

Automation in LMIC

Humaira Qurashi, Qinecsa, UK

Ushering the New Era of Pharmacovigilance

Oral Presentations

Abstract presentation: An improved method for identifying duplicates in global databases of adverse event reports for medicines and vaccines, Jim Barrett
Enhancing Local Literature Screening in Pharmacovigilance with an Automated Approach, Artem Horilyk

Parallel

Spanish session

15:30 |📍CMR International 2

S16: Avances y retos en Farmacovigilancia en la region de Latino América (Advances and Challenges in Pharmacovigilance in the Latin American Region)

Liliana Vargas, MOH Mexico

Introduction and framework

Diego Alexander Salas. Fifarma, Mexico

Regulatory harmonization in Latin America: the issues and impact in PV

Paul Alfonzo Perez, Universidad Privada Norbert Wiener, Peru

Pharmacovigilance in traditional medicine in Latin America: State of Art

Lucila Castro-Pastrana, Universidad de Las Americas Pubela, Mexico

Advances in Pharmacogenomics in Latin America

Angela Caro, President ISoP Global, Colombia

PV engagement in Latin America: some successful strategies for patient and healthcare professional engagement

Oral Presentation

Exploring the Relationship Between Medication Use and Falls Among Older Patients in Peru: A Retrospective Observational Study, Teodoro Oscanoa

Effectiveness of an automated tool for COVID-19 mRNA vaccine ESAVIs: data collection analysis and regulatory compliance in Mexico during pandemic, Betty Duarte

17:00

End of day
Conference Dinner

 

Saturday
October

05

08:30 |📍CMR Theatre

P3: Advancing Safety with New Technologies in Medical Devices and Combination Products

Omar Aimer Co-Chair

Marina Malikova, Boston University, USA

TBD

TBD

Juan Daccach, Merz, USA

The role of physicians in risk management for medical devices

Marina Malikova, Boston University, USA

Risk-based quality and safety management in clinical trials with medical devices as combination products

09:40

Coffee Break

10:10 |📍CMR Theatre

P4: The Future of Pharmacovigilance. Challenges and opportunities in a fast-changing environment from different angles

Omar Aimer Co-Chair

Maribel Salass, Bayer, USA

Monica Muñoz

Monica Munoz, US FDA, USA

US FDA perspective

Shanti Pal, WHO, Switzerland

WHO perspective

Alex Dodoo, Ghana Standards Authority, Ghana

PV in African region perspective

Luis Pinheiro, EMA, Netherlands

EMA perspective

Peter Hjelmström, UMC, Sweden

Global standardization for safer use of medicines and vaccines

11:10 |📍CMR Theatre

Special Session: Bengt Erik Wiholm Lecture

Brian Edwards, ISoP Vice President, UK

The system to optimise use of medicines and devices ultimately depends on human performance

12:00 |📍CMR Theatre

Closing Ceremony

Angela Caro, ISoP President, Colombia

Closing remarks

Omar Aimer Co-Chair

Omar Aimer, ISoP, Canada

Thank you notes

Maribel Salas, ISoP, USA

Thank you notes

Hadir Rostom, ISoP Egypt Chapter

Presentation of ISoP 2025

13:00

Lunch
End of the Conference

 

Previous Meetings
Stay In Touch